rhil Search Results


recombinant human il 6  (R&D Systems)
96
R&D Systems recombinant human il 6
Recombinant Human Il 6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 6/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant human il 6 - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
recombinant human il 1α  (R&D Systems)
93
R&D Systems recombinant human il 1α
Recombinant Human Il 1α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 1α/product/R&D Systems
Average 93 stars, based on 1 article reviews
recombinant human il 1α - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
tnf  (Proteintech)
93
Proteintech tnf
Tnf, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tnf/product/Proteintech
Average 93 stars, based on 1 article reviews
tnf - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
recombinant human il 27 protein  (R&D Systems)
94
R&D Systems recombinant human il 27 protein
Recombinant Human Il 27 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 27 protein/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant human il 27 protein - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
il 32a  (R&D Systems)
94
R&D Systems il 32a
Il 32a, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 32a/product/R&D Systems
Average 94 stars, based on 1 article reviews
il 32a - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
il 32b  (R&D Systems)
94
R&D Systems il 32b
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Il 32b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 32b/product/R&D Systems
Average 94 stars, based on 1 article reviews
il 32b - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
recombinant human il 13  (R&D Systems)
95
R&D Systems recombinant human il 13
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Recombinant Human Il 13, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 13/product/R&D Systems
Average 95 stars, based on 1 article reviews
recombinant human il 13 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
recombinant human il 3 protein r d systems  (R&D Systems)
96
R&D Systems recombinant human il 3 protein r d systems
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Recombinant Human Il 3 Protein R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human il 3 protein r d systems/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant human il 3 protein r d systems - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
recombinant proteins recombinant human il 32 gamma protein cf r d systems  (R&D Systems)
94
R&D Systems recombinant proteins recombinant human il 32 gamma protein cf r d systems
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Recombinant Proteins Recombinant Human Il 32 Gamma Protein Cf R D Systems, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant proteins recombinant human il 32 gamma protein cf r d systems/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant proteins recombinant human il 32 gamma protein cf r d systems - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
il 7  (R&D Systems)
94
R&D Systems il 7
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Il 7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 7/product/R&D Systems
Average 94 stars, based on 1 article reviews
il 7 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
il 1b  (R&D Systems)
97
R&D Systems il 1b
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Il 1b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/il 1b/product/R&D Systems
Average 97 stars, based on 1 article reviews
il 1b - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
human il6  (Proteintech)
93
Proteintech human il6
Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) <t>IL-32b</t> supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.
Human Il6, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human il6/product/Proteintech
Average 93 stars, based on 1 article reviews
human il6 - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) IL-32b supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.

Journal: The Journal of investigative dermatology

Article Title: IL-32 Supports the Survival of Malignant T Cells in Cutaneous T-cell Lymphoma.

doi: 10.1016/j.jid.2022.01.009

Figure Lengend Snippet: Figure 2. IL-32 induces CD14D APC that support malignant T-cell survival. (a) Survival of purified T cells versus PBMC from a patient with stage IV CTCL after culture with IL-32 and submitogenic IL-2. (b) IL-32b supported the survival of malignant and benign T cells and CD14þ myeloid cells. Five additional donors showed similar results. (c, d) HTS confirmed the persistence of malignant T cell TCRs in culture. (e) IL-32b enhanced the survival of benign and malignant T cells. (f, g) IL-32b induced the formation of large, activated CD14þ T cells. Similar results were observed in five additional donors. (h) The number of surviving malignant T cells was directly proportional to the number of IL-32beinduced large CD14þ cells. (i) IL-32b enhanced malignant T-cell survival by reducing apoptosis (detected by SYTOX Green). APC, antigen-presenting cell; cyt, cytokine; HTS, high throughput TCR sequencing.

Article Snippet: A total of 300,000e1,000,000 cells in 200 ml per well were cultured in round-bottom 96-well plates in the presence or absence of IL-2 (25 IU/ml, National Cancer Institute, Bethesda, MD), IL-32a (25 ng/ml; number 3040-IL-050, R&D Systems), IL-32b (25 ng/ml; number 6769-IL-025, R&D Systems), or IL-32g (25 ng/ml; number 4690-IL-025/CF, R&D Systems).

Techniques: High Throughput Screening Assay, Sequencing